(1C) 1.2: In adults with CKD (including those treated with chronic dialysis or kidney transplantation), follow-up measurement of lipid levels is not required for the majority of patients. (Not Graded) CHAPTER 2: PHARMACOLOGICAL CHOLESTEROL- LOWERING TREATMENT IN ADULTS 2.1.1: In adults aged X50 years with eGFR o60 ml/min but not treated with chronic dialysis or kidney transplantation (GFR categories G3a G5), we recommend treatment with a statin or statin/ezetimibe combination. (1A) 2.1.2: In adults aged X50 years with CKD and eGFR (GFR categories G1 G2), we recom- mend treatment with a statin. (1B) 2.2: In adults aged 18-49 years with CKD but not treated with chronic dialysis or kidney transplantation, we suggest statin treatment in people with one or more of the following (2A):  known coronary disease (myocardial infarction or coronary revascularization)  diabetes mellitus  prior ischemic stroke  estimated 10-year incidence of coronary death or non-fatal myocardial infarction 410%. 2.3.1: In adults with dialysis-dependent CKD, we suggest that statins or statin/ezetimibe combination not be 2.3.2: In patients already receiving statins or statin/ ezetimibe combination at the time of dialysis initiation, we suggest that these agents be continued. (2C) 2.4: In adult kidney transplant recipients, we suggest treatment with a statin. (2B) CHAPTER 3: ASSESSMENT OF LIPID STATUS IN CHILDREN WITH CKD 3.1: In children with newly identified CKD (including those treated with chronic dialysis or kidney transplantation), we recommend evaluation with a lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides). (1C) 3.2: In children with CKD (including those treated with chronic dialysis or kidney transplantation), we suggest annual follow-up measurement of fasting lipid levels. 